Persistent Challenges Sometimes the challenges seem neverending. In addition to the rigors of our daily lives as rheumatology health professionals—growing administrative burdens, increasing pressures to fund research and achieve balance in family and personal lives—we face a growing number of challenges related to the rapidly escalating prices of rheumatology treatments. Even more unfortunately, these costs…
Search results for: health insurance
ACR’s 2017 Advocacy Successes
In the ever-changing healthcare delivery landscape, the ACR continues to go to work on behalf of its members to ensure public policies encourage delivery of high-quality rheumatology care and treatment. With stepped-up efforts to meet with federal administrative and Congressional representatives, and broadened coalitions of partners to strengthen advocacy for key issues important to the…
Persistent Pain Merits Better Access to Psychosocial Care, Group Says
NEW YORK (Reuters Health)—People with persistent pain need better access to psychosocial care, according to a position statement from the Society of Behavioral Medicine (SBM). “Psychosocial approaches to pain management need to be available for all individuals with persistent pain in all healthcare settings,” Dr. E. Amy Janke from the University of the Sciences, in…
ACR in Action: A Look at ACR Activities That Support Your Practice
Rheumatologists working in every practice setting face a number of challenges that can seem insurmountable. How do you cost-effectively manage administrative burdens? How do you establish an efficient and effective approach to capturing quality metrics? How do you maintain the critical elements of the care you provide, such as diagnostic musculoskeletal ultrasound and patient access…
2017 ACR/ARHP Honors & Awards, Part 2
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ARHP winners about their individual contributions. In addition, we profile the new class…
Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting
SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…
Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
Rheumatologists Can Now Treat Patients Via Telemedicine
SAN DIEGO—In many regions, rheumatologists are scarce, and shortfalls will only increase. Panelists in the session, Telehealth: Can It Expand the Rheumatology Workforce?, held Nov. 6 during the 2017 ACR/ARHP Annual Meeting, believe technology can help bridge the gap. The more specific term, telemedicine, “refers to clinical care delivered from a distance,” said John A….
ACR Advocacy: Past Wins, Future Outlook
Greetings, advocates! Your government is back to work after ending a brief government shutdown by passing a short-term continuing resolution (CR), which will keep the government running at current funding levels into February. At some point, it would be great for Congress to pass a budget (instead of a CR) and to enact bipartisan plans…
Biosimilars: Still Waiting for Promise to Materialize
During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 113
- Next Page »